P.A.W. Capital’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

P.A.W. Capital’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-50,000	Closed	-$1.44M	–	68
2020 Q4	$1.44M	Sell	50,000 -30,000	-38%	-$755K	1.27%	22
2020 Q3	$1.62M	Buy	80,000 +15,000	+23%	+$366K	1.76%	22
2020 Q2	$1.95M	Sell	65,000 -40,000	-38%	-$1.44M	2.21%	18
2020 Q1	$3.3M	Sell	105,000 -5,000	-5%	-$174K	4.44%	3
2019 Q4	$5.18M	Sell	110,000 -50,000	-31%	-$1.44M	5.53%	1
2019 Q3	$1.03M	Buy	160,000 +40,000	+33%	+$334K	1.29%	25
2019 Q2	$1.47M	Buy	+120,000	New	+$1.34M	1.59%	24

Other funds holding CNST

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

P.A.W. Capital's CNST Position: Q1 2021 in Review

P.A.W. Capital sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q1 2021, closing a stake of 50,000 shares — an estimated $1.44M sold.

P.A.W. Capital first reported a position in CNST in Q2 2019 and held it in 7 quarters. The position peaked at $5.18M in Q4 2019. 131 funds tracked by Wall St. Rank hold CNST as of Q1 2021.

P.A.W. Capital reported no remaining Constellation Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
P.A.W. Capital sold 50,000 Constellation Pharmaceuticals, Inc. shares in Q1 2021, an estimated $1.44M.
P.A.W. Capital first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2019 and held it in 7 quarters.
P.A.W. Capital's Constellation Pharmaceuticals, Inc. position peaked at $5.18M in Q4 2019.
131 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q1 2021.

Based on P.A.W. Capital's 13F filing for Q1 2021, filed 10 May 2021.